Trial Profile
RIAPRE - A Non-interventional Registry on the Anticoagulation Treatment in High Risk Elective Percutaneous Coronary Interventions
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2013
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms RIAPRE
- Sponsors Takeda Pharmaceuticals International GmbH
- 10 May 2012 New trial record
- 04 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.